Julian English

Orexo announces positive outcome from in vivo study of OX390

MEKanistic Therapeutics announces FDA clearance of IND for MTX-531, enabling phase 1 trials in advanced solid tumours

Matter Bio files first IND for Lm-LLO-TT, advancing first-in-human phase 1/2a study in patients with pancreatic cancer

Myosin Therapeutics initiates phase 1/2 trial of MT-125 targeting non-muscle myosin II in newly diagnosed glioblastoma

New clinical study shows pasteurised Akkermansia muciniphila MucT supports weight loss maintenance

Remepy reports strong clinical phase 2a results for Hybridopa, a first-in-class hybrid drug for Parkinson’s disease

BioMarin announces positive phase 3 pivotal study results for Voxzogo (vosoritide) in children with hypochondroplasia

Atossa Therapeutics announces acceptance of manuscript highlighting utrophin-modulation potential of (Z)-Endoxifen in Duchenne Muscular Dystrophy

Eli Lilly’s triple agonist, retatrutide, delivered powerful weight loss in pivotal phase 3 obesity trial

Kelun-Biotech announces phase 3 trial of Sacituzumab Tirumotecan versus chemotherapy as first-line treatment for advanced TNBC met primary endpoint of PFS